SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.33-8.6%Jan 16 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (9298)3/21/1999 8:40:00 AM
From: StockDoc  Read Replies (3) of 17367
 
Hello everybody, just visiting from the past. Interesting discussion and calculation. Be aware that the mortality of bacterial meningitis averages 11% with current treatment modalities and should drop below 10% as soon as some novel and apparently helpful ICU procedures (e.g, peritoneal ventillation in D.I.C., etc.) gain wider acceptance. Could you recalculate with 10% in the "placebo" arm and assume a 10% improvement by BPI arm? By the way, what's the thinking on this board about the apparent efficacy of protein C, antithrombin III and, maybe, activated protein C (Baxter, Genzyme, and Eli Lilly) in bacterial sepsis?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News